Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage
biotechnology company pioneering a new class of immuno-oncology
agents that combine the targeting precision of antibodies with the
power of both the innate and adaptive immune systems, today
announced the presentation of interim clinical data from the
company’s ongoing Phase 1/2 study of BDC-1001, the company’s lead
immune-stimulating antibody conjugate (ISAC) in a poster session at
the European Society for Medical Oncology Immuno-Oncology (ESMO
I-O) Congress 2021, being held virtually from Dec. 6-11, 2021. The
lead author for the poster is Manish Sharma, M.D., START Midwest,
with contributions from Ecaterina Dumbrava, M.D., MD Anderson
Cancer Center, and other colleagues from the U.S. and South Korea.
The company reported data from 57 subjects participating in an
ongoing Phase 1/2 study of BDC-1001, across 16 different types of
HER2-expressing solid tumors. BDC-1001 demonstrated a favorable
safety and tolerability profile at all evaluated doses and
schedules, showing early signs of clinical activity with
corresponding biomarker changes in the tumor
microenvironment of post-treatment tumor biopsies. BDC-1001 is an
immune-stimulating antibody conjugate (ISAC) comprising a
HER2-targeting biosimilar of trastuzumab conjugated with a
non-cleavable linker to an innovative TLR7/8 agonist.
“The favorable safety profile and early indications of clinical
disease control in the BDC-1001 study are encouraging,” said Dr.
Sharma, Associate Director of Clinical Research at START Midwest.
“There is a clear need for well tolerated, durable treatments in
the fight against cancer and I’m excited to see if BDC-1001 can
deliver on that potential as we explore higher drug exposure
levels.”
The poster presentation at ESMO I-O reported new safety,
pharmacokinetic/pharmacodynamic, and efficacy results for the
ongoing Phase 1 dose-escalation portion of the BDC-1001 monotherapy
trial. Fifty-seven subjects have been treated at increasing dose
levels up to 20 mg/kg every three weeks and 12 mg/kg every two
weeks, and data from these subjects demonstrate that:
- BDC-1001 continues to have a
favorable safety and tolerability profile with mild (grade 1/grade
2) infusion related reactions in some patients and no dose-limiting
toxicities at dose levels up to 20 mg/kg every three weeks and 12
mg/kg every two weeks. There was no indication of cytokine release
syndrome (CRS), and a maximum tolerated dose (MTD) has not been
reached.
- Early signs of clinical activity are
noted in 13 of 40 tumor evaluable subjects with one durable partial
response maintained through 52 weeks and multiple subjects
achieving stable disease for >12 weeks.
- The pharmacokinetic (PK) data
demonstrate increasing peak drug levels with increasing dose, and
linearity of PK above the 5 mg/kg dose level. Clinical PK modeling
predicts that target exposure levels can be achieved with weekly
dosing.
- Plasma and tissue biomarker results
show increase in multiple biomarkers indicative of myeloid cell and
TLR 7/8 activation that is consistent with BDC-1001’s mechanism of
action. Increasing drug exposure correlates with increases in
plasma cytokines and corresponding biomarker changes in the tumor
microenvironment of multiple post-treatment tumor biopsies, with
intriguing signs of clinical disease control.
These encouraging data point to the need for increased drug
exposure to optimize clinical benefit. The favorable safety profile
of BDC-1001 allows for continued enrollment in the dose escalation
portion of the study, and the Company’s refined PK model based on
data from more than 50 patients predicts that weekly administration
will provide BDC-1001 exposures at or above the target exposure
threshold. The data also support initiation of the combination
therapy study with nivolumab (PD-1 inhibitor).
“Bolt Biotherapeutics is committed to agile clinical development
based on data. In this Phase 1/2 study of BDC-1001, we have gained
tremendous insight into the ability of this novel candidate to
mobilize the patient’s immune system in targeting the tumor and its
microenvironment. The increases in myeloid cell infiltration and
repolarization of macrophages we’ve seen in multiple post-treatment
biopsies are provocative and consistent with our proposed mechanism
of action,” said Edith Perez, M.D., Chief Medical Officer of Bolt
Biotherapeutics. “We look forward to exploring weekly dosing as we
get closer to determining the recommended Phase 2 dose for BDC-1001
as monotherapy, and to initiating combination therapy with a
checkpoint inhibitor.”
Presentation DetailsTitle:
Preliminary results from a phase 1/2 study of BDC-1001, a novel
HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC),
in patients (pts) with advanced HER2-expressing solid tumors
Lead author: Manish R. Sharma,
M.D.Presentation Number:
164PTiming: On-demand access beginning Dec. 6 at
12:00 p.m. CET.
The poster presentation will be available on the ESMO I-O
conference website and on Bolt’s website.
Conference Call and Webcast Details
Bolt Biotherapeutics management will host a conference call for
the investment community, in conjunction with the now virtual ESMO
Immuno-Oncology Congress 2021, to discuss emerging clinical data
and insights from the ongoing Phase 1/2 study today, Monday,
December 6, 2021, at 8:00 a.m. ET/5 a.m. PT.
The conference call can be accessed by dialing +1 (833) 665-0609
within the U.S. or Canada or by dialing +1 (929) 517-0400 from
international locations. The passcode for the call is 2633068. A
live webcast, including slides, will be available on the Events
& Presentations page of Bolt Biotherapeutic’s website at
www.boltbio.com. An archived replay can be accessed for 30 days
following the webcast.
About the Boltbody™ Immune-Stimulating Antibody
Conjugate (ISAC) PlatformISACs are a new category of
immunotherapy that combines the precision of antibody targeting
with the strength of the innate and adaptive immune systems.
Boltbody ISACs comprise three primary components: a tumor-targeting
antibody, a non-cleavable linker, and a proprietary immune
stimulant to activate the patient’s innate immune system. By
initially targeting a single marker on the surface of a patient’s
tumor cells, an ISAC can create a new immune response by activating
and recruiting myeloid cells. The activated myeloid cells start a
feed-forward loop by releasing cytokines and chemokines, chemical
signals that attract other immune cells and lower the activation
threshold for an immune response. This reprograms the tumor
microenvironment and invokes an adaptive immune response that
targets the tumor, with the goal of durable responses for patients
with cancer.
About Bolt Biotherapeutics, Inc.Bolt
Biotherapeutics, Inc. is a clinical-stage biotechnology company
pioneering a new class of immuno-oncology agents that combine the
targeting precision of antibodies with the power of both the innate
and adaptive immune systems. Bolt’s proprietary Boltbody™
Immune-stimulating Antibody Conjugates (ISACs) are designed to
target tumor cells for elimination by myeloid cells, which then
activates the myeloid cells to recruit the adaptive immune system
in the anti-tumor response. This leads to the conversion of
immunologically “cold” tumors to “hot” tumors. Bolt’s lead
candidate, BDC-1001, is a Boltbody ISAC comprised of a
HER2-targeting biosimilar of trastuzumab conjugated with a
non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists
for the treatment of patients with HER2-expressing solid tumors.
Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and
a pipeline of other immuno-oncology products.
Forward-Looking Statements
This press release contains forward-looking statements about us
and our industry that involve substantial risks and uncertainties
and are based on our beliefs and assumptions and on information
currently available to us. All statements other than statements of
historical facts contained in this press release, including
statements regarding optimizing the dose and finding the
recommended Phase 2 dose for BDC-1001 and the potential initiation
of an additional combination dose escalation study by year-end, are
forward-looking statements. In some cases, you can identify
forward-looking statements because they contain words such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
or “would,” or the negative of these words or other similar terms
or expressions. Forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements represent our current beliefs, estimates
and assumptions only as of the date of this press release and
information contained in this press release should not be relied
upon as representing our estimates as of any subsequent date. These
statements, and related risks, uncertainties, factors and
assumptions, include, but are not limited to the potential product
candidates that we develop may not progress through clinical
development or receive required regulatory approvals within
expected timelines or at all; clinical trials may not confirm any
safety, potency or other product characteristics described or
assumed in this press release; such product candidates may not be
beneficial to patients or become commercialized. These risks are
not exhaustive. Except as required by law, we assume no obligation
to update these forward-looking statements, or to update the
reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new
information becomes available in the future. Further information on
factors that could cause actual results to differ materially from
the results anticipated by our forward-looking statements is
included in the reports we have filed or will file with the SEC,
including our Annual Report on Form 10-K for the year ended
December 31, 2020. These filings, when available, are available on
the investor relations section of our website at
investors.boltbio.com and on the SEC’s website at www.sec.gov.
Opdivo® is a trademark of Bristol-Myers Squibb Company.
Investor Relations and Media Contacts:Karen L.
BergmanVice President, Communications and Investor RelationsBolt
Biotherapeutics, Inc.650-665-9295kbergman@boltbio.com
Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Maggie Beller or David SchullRusso Partners,
LLC646-942-5631maggie.beller@russopartnersllc.comdavid.schull@russopartnersllc.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Apr 2023 to Apr 2024